These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18034311)

  • 81. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
    Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
    J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
    Frye RF; Branch RA
    Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
    Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ
    Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes.
    AlRabiah H; Ahad A; Mostafa GAE; Al-Jenoobi FI
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):707-713. PubMed ID: 29744741
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Metabolism of a New Antiaggregant, Indolinone Derivative.
    Bykov VV; Leonov KA; Serebrov VY; Chernysheva GA; Smol'yakova VI; Solov'ev MA; Udut EV; Fisenko VP; Udut VV
    Bull Exp Biol Med; 2020 Apr; 168(6):739-742. PubMed ID: 32333310
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
    Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
    Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
    Yamazaki H; Shimada T
    Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.
    Salsali M; Holt A; Baker GB
    Cell Mol Neurobiol; 2004 Feb; 24(1):63-76. PubMed ID: 15049511
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6.
    Manga N; Duffy JC; Rowe PH; Cronin MT
    SAR QSAR Environ Res; 2005; 16(1-2):43-61. PubMed ID: 15844442
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes.
    Misaka S; Kawabe K; Onoue S; Werba JP; Giroli M; Tamaki S; Kan T; Kimura J; Watanabe H; Yamada S
    Drug Metab Pharmacokinet; 2013; 28(3):244-9. PubMed ID: 23268924
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Descriptors of Cytochrome Inhibitors and Useful Machine Learning Based Methods for the Design of Safer Drugs.
    Beck TC; Beck KR; Morningstar J; Benjamin MM; Norris RA
    Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34067565
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule.
    Mishra NK; Agarwal S; Raghava GP
    BMC Pharmacol; 2010 Jul; 10():8. PubMed ID: 20637097
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Predictive models for cytochrome p450 isozymes based on quantitative high throughput screening data.
    Sun H; Veith H; Xia M; Austin CP; Huang R
    J Chem Inf Model; 2011 Oct; 51(10):2474-81. PubMed ID: 21905670
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors.
    Nath A; Zientek MA; Burke BJ; Jiang Y; Atkins WM
    Drug Metab Dispos; 2010 Dec; 38(12):2195-203. PubMed ID: 20841376
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A novel chemometric method for the prediction of human oral bioavailability.
    Xu X; Zhang W; Huang C; Li Y; Yu H; Wang Y; Duan J; Ling Y
    Int J Mol Sci; 2012; 13(6):6964-6982. PubMed ID: 22837674
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Generation of new inhibitors of selected cytochrome P450 subtypes-
    Danel T; Wojtuch A; Podlewska S
    Comput Struct Biotechnol J; 2022; 20():5639-5651. PubMed ID: 36284709
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Ligand-Based Site of Metabolism Prediction for Cytochrome P450 2D6.
    Rydberg P; Olsen L
    ACS Med Chem Lett; 2012 Jan; 3(1):69-73. PubMed ID: 24900373
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Evaluation of descriptors and classification schemes to predict cytochrome substrates in terms of chemical information.
    Block JH; Henry DR
    J Comput Aided Mol Des; 2008; 22(6-7):385-92. PubMed ID: 18217216
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A Robust Machine Learning Framework Built Upon Molecular Representations Predicts CYP450 Inhibition: Toward Precision in Drug Repurposing.
    Ouzounis S; Panagiotopoulos V; Bafiti V; Zoumpoulakis P; Cavouras D; Kalatzis I; Matsoukas MT; Katsila T
    OMICS; 2023 Jul; 27(7):305-314. PubMed ID: 37406257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.